Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
AURKA 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
Latest Hotspot
8 min read
AURKA 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
AURKA 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Read →
E2F1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
Latest Hotspot
8 min read
E2F1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
E2F1 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Read →
RB1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
Latest Hotspot
8 min read
RB1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
RB1 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Read →
CCNE1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
Latest Hotspot
8 min read
CCNE1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
CCNE1 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Read →
CCND1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
Latest Hotspot
8 min read
CCND1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
CCND1 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Read →
CDK9 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
Latest Hotspot
8 min read
CDK9 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
CDK9 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Read →
CDK2 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
Latest Hotspot
8 min read
CDK2 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
CDK2 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Read →
CDK6 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
Latest Hotspot
8 min read
CDK6 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
CDK6 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Read →
CDK4 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
Latest Hotspot
8 min read
CDK4 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
CDK4 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Read →
DDR2 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
Latest Hotspot
8 min read
DDR2 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
DDR2 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Read →
DDR1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
Latest Hotspot
8 min read
DDR1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
DDR1 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Read →
TEK 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
Latest Hotspot
8 min read
TEK 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
TEK 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Read →